logo-loader
viewHemoGenyx Pharmaceuticals

Hemogenyx appoints Marc Feldmann, pioneer of anti-TNF therapy for rheumatoid arthritis, as its new executive chairman

The biotechnology group said Feldmann has a “unique blend of scientific, medical and commercial experience and expertise”

hemigenyx
Following the changes, Robin Campbell, currently Hemogenyx's chairman, will become a non-executive director

HemoGenyx Pharmaceuticals PLC (LON:HEMO) has announced the appointment of Sir Marc Feldmann as its new executive chairman with effect from 9 April 2018.

The biotechnology group noted that Feldmann has a “unique blend of scientific, medical and commercial experience and expertise”, pointing out that he shares the academic credit for inventing and developing an anti-TNF therapy for rheumatoid arthritis - the first use of monoclonal antibodies in a common disease.

READ: Hemogenyx shares leap as it signs collaboration deal with major US biotechnology company

HemoGenyx said Feldmann was previously chairman of the company’s scientific advisory board and has a “remarkably broad experience” of discovering new medicines, testing ideas and leading clinical trials.

Following the changes, Robin Campbell, currently Hemogenyx's chairman, will become a non-executive director and Adrian Beeston, its non-executive director, will step down from the board, both with the immediate effect.

Vladislav Sandler, HemoGenyx's CEO, said: “Since Sir Marc has been at the forefront of  promoting effective scientific-medical-pharmaceutical interactions, he has built up a huge network of friends and collaborators who meet regularly in Oxford and they will help Hemogenyx grow and go clinical.”   

In early morning trading, the company’s shares were up 6.4% at 2.90p.

Quick facts: HemoGenyx Pharmaceuticals

Price: 6.79 GBX

LSE:HEMO
Market: LSE
Market Cap: £29.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read